BIOA
BioAge Labs, Inc. Common StockBIOA
BIOA
About: Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1213.35% more ownership
Funds ownership: 0% [Q2] → 1213.35% (+1213.35%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
30%
upside
Avg. target
$7
30%
upside
High target
$7
30%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
Citigroup Samantha Semenkow 20% 1-year accuracy 3 / 15 met price target | 30%upside $7 | Neutral Downgraded | 9 Dec 2024 |
Jefferies Roger Song 19% 1-year accuracy 3 / 16 met price target | 30%upside $7 | Hold Downgraded | 9 Dec 2024 |
Financial journalist opinion
Based on 365 articles about BIOA published over the past 30 days
Neutral
PRNewsWire
54 minutes ago
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit
NEW YORK , Jan. 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to the registration statement for BioAge's initial public offering conducted on September 26, 2024 (the "IPO"), of the important March 10, 2025 lead plaintiff deadline. So what: If you purchased BioAge stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Accesswire
1 hour ago
Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=125114&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
2 hours ago
BIOA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of BioAge Labs, Inc. to Contact the Firm Today!
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired BioAge securities pursuant to the registration statement and prospectus issued in connection with the Company's September 26, 2024 initial public offering ("IPO").
Neutral
Accesswire
15 hours ago
BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA
NEW YORK, NY / ACCESS Newswire / January 25, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=125081&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
22 hours ago
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against BioAge Labs, Inc.
LOS ANGELES, CA / ACCESS Newswire / January 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ("IPO") conducted on September 26, 2024, are encouraged to contact the firm before March 10, 2025.
Neutral
GlobeNewsWire
1 day ago
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BIOA
NEW YORK, Jan. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public offering conducted on September 26, 2024 (the “IPO”), of the important March 10, 2025 lead plaintiff deadline.
Neutral
PRNewsWire
1 day ago
BIOA INVESTOR DEADLINE: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO , Jan. 25, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ: BIOA) stock pursuant and/or traceable to BioAge Labs' registration statement issued in connection with BioAge Labs' initial public offering (the "IPO") held on September 26, 2024, have until Monday, March 10, 2025 to seek appointment as lead plaintiff of the BioAge Labs class action lawsuit. Captioned Soto v.
Neutral
Accesswire
1 day ago
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIOA
NEW YORK CITY, NY / ACCESS Newswire / January 25, 2025 / WHY: New York, N.Y., January 25, 2025.
Neutral
GlobeNewsWire
1 day ago
BIOA SHAREHOLDER REPORT: A Class Action was filed on behalf of BioAge Labs Investors – Contact BFA Law before March 10 Legal Deadline (NASDAQ:BIOA)
NEW YORK, Jan. 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Neutral
Accesswire
1 day ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioAge Labs, Inc. (BIOA) Shareholders
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=125013&wire=1 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™